CLINICAL TRIALS PROFILE FOR DIETHYLPROPION HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for DIETHYLPROPION HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00248092 ↗ | Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse | Completed | New River Pharmaceuticals | Phase 1/Phase 2 | 2006-01-01 | This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. NRP104 is an investigational drug. This means that it has not been approved by the U.S. Food and Drug Administration (FDA). Healthy people, between the ages of 18 and 55 with histories of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to treat narcolepsy (excessive sleepiness) and for weight loss. |
| NCT02039960 ↗ | PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011 | Completed | GlaxoSmithKline | 2013-11-01 | Bupropion hydrochloride was first approved on 30 December 1985 in United States for depression and is currently approved in 80 countries. Bupropion has also subsequently been approved for smoking cessation and for seasonal affective disorder. Cumulative exposure to bupropion is estimated at approximately 97.3 million patient exposures up to 31 December 2012. Bupropion hydrochloride is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine. Its mechanism of action and its structural similarities to diethylpropion, amphetamines, and cocaine, bupropion resembles stimulants in many respects, leading to concerns about potential abuse of the product. Abuse potential had been part of the Benefit Risk Management Plan for bupropion up until 2003 and at that point, had no longer been regarded as a potential risk that required additional/further evaluation outside standard pharmacovigilance monitoring. The current European Risk Management Plan also states that standard pharmacovigilance monitoring applies to abuse potential. Monitoring has shown a recent increase in the number of spontaneous reports from the Adverse Event reporting System (AERS) of drug abuse. The bupropion team agreed that although the numbers of abuse reports was small relative to the total number of reports for bupropion in OCEANS, there was sufficient information in AERS to warrant investigation of the potential effect on public health. To investigate the degree of misuse and abuse of bupropion (including non-oral routes of administration) in the United States, the Drug Abuse Warning Network will be used to examine the study period 2004-2011. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DIETHYLPROPION HYDROCHLORIDE
Condition Name
Clinical Trial Locations for DIETHYLPROPION HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for DIETHYLPROPION HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for DIETHYLPROPION HYDROCHLORIDE
Sponsor Name
